E-Selectin-Overexpressing Mesenchymal Stem Cell Therapy Confers Improved Reperfusion, Repair, and Regeneration in a Murine Critical Limb Ischemia Model
Overview
Authors
Affiliations
Aims: Novel cell-based therapeutic angiogenic treatments for patients with critical limb ischemia may afford limb salvage. Mesenchymal stem cells (MSCs) do not overexpress E-selectin; however, we have previously demonstrated the cell-adhesion molecule's vital role in angiogenesis and wound healing. Thus, we created a viral vector to overexpress E-selectin on MSCs to increase their therapeutic profile.
Methods And Results: Femoral artery ligation induced hind limb ischemia in mice and intramuscular injections were administered of vehicle or syngeneic donor MSCs, transduced with an adeno-associated viral vector to express either GFP (MSC) or E-selectin-GFP (MSC). Laser Doppler Imaging demonstrated significantly restored reperfusion in MSC-treated mice vs. controls. After 3 weeks, the ischemic limbs in mice treated with MSC had increased footpad blood vessel density, hematoxylin and eosin stain (H&E) ischemic calf muscle sections revealed mitigated muscular atrophy with restored muscle fiber size, and mice were able to run further before exhaustion. PCR array-based gene profiling analysis identified nine upregulated pro-angiogenic/pro-repair genes and downregulated gene in MSC-treated limb tissues, indicating that the therapeutic effect is likely achieved upregulation of pro-angiogenic cytokines and downregulation of inflammation.
Conclusion: This innovative cell therapy confers increased limb reperfusion, neovascularization, improved functional recovery, decreased muscle atrophy, and thus offers a potential therapeutic method for future clinical studies.
Li D, Li Y, Lv D, Deng T, Zeng X, You L J Tissue Eng. 2024; 15:20417314241268917.
PMID: 39329066 PMC: 11425747. DOI: 10.1177/20417314241268917.
Narrative Review of Biological Markers in Chronic Limb-Threatening Ischemia.
Popescu A, Rata A, Barac S, Popescu R, Onofrei R, Vlad C Biomedicines. 2024; 12(4).
PMID: 38672153 PMC: 11047884. DOI: 10.3390/biomedicines12040798.
Huerta C, Voza F, Ortiz Y, Liu Z, Velazquez O Front Cardiovasc Med. 2023; 10:1236345.
PMID: 37600026 PMC: 10436297. DOI: 10.3389/fcvm.2023.1236345.
Huerta C, Voza F, Ortiz Y, Liu Z, Velazquez O Front Cardiovasc Med. 2023; 10:1113982.
PMID: 36818343 PMC: 9930203. DOI: 10.3389/fcvm.2023.1113982.
Song J, Liu J, Cui C, Hu H, Zang N, Yang M J Cachexia Sarcopenia Muscle. 2023; 14(2):915-929.
PMID: 36708027 PMC: 10067482. DOI: 10.1002/jcsm.13177.